Claim construction after Amgen
What does the House of Lords decision in Kirin-Amgen mean for claim construction? Kate Beattie and Chris Forsyth, Freshfields Bruckhaus Deringer, explain
The House of Lords has demonstrated the critical importance of claim construction in patent litigation in Kirin-Amgen Inc
and others (Amgen) v Hoechst Marion Roussel Limited and others (TKT). Lord Hoffmann’s judgment defines the approach to determining
the scope of claims. His decision tightens the traditional infringement versus validity squeeze’ on patentees.
The rest of this document is only available to i-law.com online
If you are already a subscriber, please enter your details below to log in.